Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management - PubMed
3 days ago
- #Oncology Update
- #Diagnosis and Management
- #Plasmablastic Lymphoma
- Plasmablastic lymphoma (PBL) is a rare, aggressive, CD20-negative lymphoma with poor prognosis, often associated with HIV infection but can also occur in immunocompetent individuals.
- Diagnosis relies on high clinical suspicion and pathological confirmation, with frequent detection of EBV-encoded RNA (EBER) expression and MYC gene rearrangements; differential diagnoses include EBV+ diffuse large B-cell lymphoma and other similar lymphomas.
- Risk factors for worse survival include age ≥ 60 years, advanced clinical stage, and high International Prognostic Index scores.
- Recommended management involves combination chemotherapy regimens like infusional EPOCH, with potential improvements from adding bortezomib or daratumumab; B-cell maturation antigen-targeted therapies show early efficacy, and participation in clinical trials is encouraged.